The effect of Levothyroxine on the infant development status in pregnant women with autoimmune non overt thyroid disease

Assessment of the effect of Levothyroxine on the infant development status in pregnant women with autoimmune non overt thyroid disease

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017090414849N6

Enrollment

1600

Registered

2017-10-14

Start date

2017-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid disorders. Disorder of thyroid, unspecified

Interventions

Intervention 1: Intervention group will treat with Levoxine (Levothyroxine sodium). These patients will receive a daily dose of 0.5 µg per kg if they have TSH 2.0 µIU per mL or a TPOAb titer exceeding

Treatment - Drugs

Intervention group will treat with Levoxine (Levothyroxine sodium). These patients will receive a daily dose of 0.5 µg per kg if they have TSH 2.0 µIU per mL or a TPOAb titer exceeding 1500 IU per mL.

There is no intervention for the control group.

Eligibility

Sex/Gender

Female

Age

15 Years to 46 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: pregnant women during the first 20 weeks of pregnancy. Exclusion criteria: multiple pregnancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Communication developmental status. Timepoint: Since 4 months after birth. Method of measurement: Ages and Stages Questionnaire (ASQ).;Gross motor developmental status. Timepoint: Since 4 months after birth. Method of measurement: Ages and Stages Questionnaire (ASQ).;Fine motor developmental status. Timepoint: Since 4 months after birth. Method of measurement: Ages and Stages Questionnaire (ASQ).;Problem solving developmental status. Timepoint: Since 4 months after birth. Method of measurement: Ages and Stages Questionnaire (ASQ).;Personal, social developmental status. Timepoint: Since 4 months after birth. Method of measurement: Ages and Stages Questionnaire (ASQ).	—

Measure

Time frame

Communication developmental status. Timepoint: Since 4 months after birth. Method of measurement: Ages and Stages Questionnaire (ASQ).;Gross motor developmental status. Timepoint: Since 4 months after birth. Method of measurement: Ages and Stages Questionnaire (ASQ).;Fine motor developmental status. Timepoint: Since 4 months after birth. Method of measurement: Ages and Stages Questionnaire (ASQ).;Problem solving developmental status. Timepoint: Since 4 months after birth. Method of measurement: Ages and Stages Questionnaire (ASQ).;Personal, social developmental status. Timepoint: Since 4 months after birth. Method of measurement: Ages and Stages Questionnaire (ASQ).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSima Nazarpour

Research Institute for Endocrine Sciences

snazarpour@gmail.com+98 21 2243 2500

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 4, 2026